Wilde Henry, Khawplod Pakamatz, Hemachudha Thiravat, Sitprija Visith
Queen Saovabha Memorial Institute (Thai Red Cross Society) and Department of Medicine, Chulalongkorn University, Bangkok, Thailand.
Clin Infect Dis. 2002 Feb 15;34(4):477-80. doi: 10.1086/324628. Epub 2002 Jan 7.
The last remaining international manufacturer of equine rabies immunoglobulin (ERIG) discontinued production in 2001. However, ERIG remains an essential biological that has no substitute other than human rabies immunoglobulin (HRIG), which is in short supply and virtually unaffordable in developing countries. Physicians in regions where canine rabies is endemic and neither ERIG nor HRIG is available are providing less-than-optimal treatment to patients exposed to rabies. If no immunoglobulin is available, they have only 1 therapy option: use of a vaccine schedule that produces the highest and, hopefully, earliest neutralizing antibody response. However, treatment failures must still be expected. Early, aggressive wound cleansing and more intensive efforts at canine control and are ever more important. Countries that have the resources to manufacture their own rabies immunoglobulins must be encouraged to do so.
马狂犬病免疫球蛋白（ERIG）的最后一家国际生产商于2001年停产。然而，ERIG仍然是一种必不可少的生物制品，除人狂犬病免疫球蛋白（HRIG）外没有其他替代品，而HRIG在发展中国家供应短缺且几乎无法负担。在犬类狂犬病流行且既没有ERIG也没有HRIG的地区，医生对暴露于狂犬病的患者提供的治疗并不理想。如果没有免疫球蛋白，他们只有一种治疗选择：采用能产生最高且有望最早产生中和抗体反应的疫苗接种方案。然而，仍可能出现治疗失败的情况。早期积极的伤口清洗以及加强犬类控制工作变得愈发重要。必须鼓励有资源自行生产狂犬病免疫球蛋白的国家这么做。
